Navigation Links
NeurogesX Reports Second Quarter 2008 Results
Date:8/13/2008

Second Quarter 2008 Corporate Highlights: - European marketing application under review for NGX-4010 in peripheral

neuropathic pain - NGX-4010 NDA for PHN on track for submission in second half of 2008

- IND submitted and opened for NGX-1998 liquid capsaicin formulation

- Phase 1 clinical trial of NGX-1998 initiated - Journal Neurology published positive Phase 3 data on NGX-4010 in HIV-DSP

SAN MATEO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the quarter ended June 30, 2008.

In the second quarter of 2008, the Company continued on its path toward potential commercialization of its lead product candidate, NGX-4010, a dermal capsaicin patch designed for the treatment of certain neuropathic pain conditions. On the U.S. regulatory front, the Company has been preparing a New Drug Application (NDA) to support marketing approval of NGX-4010 for the treatment of post-herpetic neuralgia (PHN), and is on track to submit an NDA to the U.S. Food and Drug Administration (FDA) later this year.

The Company continues to pursue the European approval of its Marketing Authorization Application (MAA) for NGX-4010 in neuropathic pain, which the European Medicines Agency (EMEA) accepted for review in September 2007. In September of 2008, the Company, with the EMEA's agreement, plans to submit responses to the regulatory agency's Day 120 questions, which are part of the review process for the MAA.

In addition to focusing on regulatory activities for NGX-4010, NeurogesX has made significant progress with
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Report Second Quarter 2008 Financial Results
2. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
3. NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. NeurogesX Reports First Quarter 2008 Results
5. NeurogesX to Report First Quarter 2008 Financial Results
6. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
7. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
8. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX Closes $25 Million Private Placement
11. NeurogesX, Inc. Announces $25 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary ... at the specialized Wolvega Horse Clinic. , Due to ... was ruptured 90% and her deep digital flexor tendon ... sentence for a horse. , The clinic has performed ... This revolutionary regenerative option for ruptured tendons has ...
(Date:9/19/2014)... simple. From crop yields to disease risks, the biological ... "complex traits." Just as for heightthe textbook example of ... disease are shaped by multiple genetic and environmental influences, ... track down such genes, geneticists typically mate two individuals ... and a small mouseand then study their descendents, looking ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2
... Md., Sept. 2 Micromet, Inc.,(Nasdaq: MITI ... novel, proprietary antibodies for the treatment of cancer,inflammation ... A. Phillips as Senior Vice President and Chief ... of the Company,s board of directors,since 2000, and ...
... a New Jersey-based,leading provider of prescription co-pay programs ... significantly expanded the scope of,the lawsuit that it ... the State,of New York, County of New York, ... of McKesson Corporation. PSKW is,now seeking, in addition ...
... The BEAUTIFUL study: a step further in title ... BEAUTIFUL study: efficacy of session title ivabradine in reduction of cardiovascular ... among patients with stable coronary ... dysfunction, ESC Hotline ...
Cached Biology Technology:Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 3
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... how many times it,s demonstrated, it,s still hard ... , But by using a signaling system called ... behavior to suit their population. In short, some ... and act accordingly. , Once the population of ... from innocuous to pathogenic, or from unhelpful to ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... have come up with a new twist in their efforts ... DNA genetic code. They have developed the first, versatile DNA ... key to unlocking the vital code behind human heredity and ... director of the Biodesign Institute,s Center for Single Molecule Biophysics, ...
... 2010) For years, doctors have warned patients to finish ... "superbug" that can mount a more powerful defense against the ... engineers indicates that treating bacteria with levels of antibiotics insufficient ... wide range of antibiotics. In the Feb. 12 issue ...
... help save the sight of patients with a type of ... University of Leeds found that the TSPAN12 gene is faulty ... Vitreoretinopathy), which affects the development of the eye. While ... of the same family may carry the faulty gene without ...
Cached Biology News:ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 2ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 3Low levels of antibiotics cause multidrug resistance in 'superbugs' 2Low levels of antibiotics cause multidrug resistance in 'superbugs' 3New gene discovery could help to prevent blindness 2
... Ambions 96 well Magnetic-Ring Stand is ... 96 well U-bottom microplates. The stand has ... 96 well microtiter plate footprint. The use ... enables fast and easy magnetic separation. With ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... is a versatile and easy-to use enzyme, ... GCpro Taq DNA Polymerase is prepared from ... containing the DNA polymerase I gene from ... processive 5'-3' DNA polymerase activity. Its inherent ...
Biology Products: